Page 18 - Priority Review News Today

Three oral presentations and seven posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic...

Results Reflect Continued Strength of In-Line and New Products, Pipeline Execution and Business Development Activity, Supporting Growth Momentum into 2024   Reports Fourth Quarter Revenues of...

Validation is supported by data from Phase 3 innovaTV 301 trial ...

Enhertu is under Priority Review for the treatment of previously treated adults with unresectable or metastatic HER2+ IHC 3+ solid tumors.

Afami-cel is an autologous T-cell therapy designed to target cancer cells in solid tumors expressing melanoma-associated antigen A4.

The PDUFA date refers to the deadline set by the US Food and Drug Administration for reviewing drug applications.

Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022; Excluding...

Following the January 25, 2024 approval of dupilumab for eosinophilic esophagitis in patients 1-11 years of age, a trio of pediatric gastroenterologists shares their thoughts on the new indication, their anticipated priority of use, and potential hurdles to optimal treatment uptake.

Merck stock jumped to a 52-week high at the opening of trading Thursday morning after the company released fourth quarter and full year results.

Liso-cel sBLAs for indications in relapsed/refractory FL and MCL after exposure to a BTK inhibitor have received priority review from the FDA.